Latest Cetuximab Stories
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity
UVA study’s surprising finding: Direct treatment of tumor prolongs survival. Charlottesville, VA (PRWEB) March 11, 2014 Contrary to the standard approach
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.